| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 123 | 122 | 114 | 485 | 131 | 129 | 171 | 144 | 134 | 184 | 144 | 173 | 136 | 234 | 158 | 1,821 | 151 | 143 | 157 | 163 | 163 | 149 | 159 | 150 | 122 | 155 | 170 | 169 | 184 |
| Expenses | 116 | 179 | 87 | 258 | 104 | 149 | 132 | 150 | 111 | 144 | 127 | 167 | 134 | 226 | 144 | 171 | 191 | 109 | 124 | 135 | 140 | 147 | 151 | 143 | 130 | 140 | 156 | 159 | 168 |
| EBITDA | 7 | -57 | 27 | 228 | 27 | -20 | 39 | -6 | 23 | 40 | 17 | 6 | 2 | 8 | 14 | 1,650 | -40 | 34 | 33 | 29 | 24 | 2 | 8 | 8 | -8 | 14 | 14 | 9 | 16 |
| Operating Profit % | -17 % | -48 % | 21 % | -110 % | 17 % | -19 % | 21 % | -19 % | 16 % | 21 % | 11 % | 1 % | -1 % | 3 % | 8 % | -21 % | -72 % | -4 % | -8 % | -4 % | -8 % | -2 % | -0 % | -4 % | -12 % | 5 % | 5 % | -20 % | -1 % |
| Depreciation | 14 | 14 | 52 | 13 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 |
| Interest | 25 | 29 | -14 | 26 | 41 | 42 | 47 | 45 | 45 | 48 | 46 | 47 | 48 | 50 | 52 | 31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -33 | -99 | -11 | 189 | -25 | -73 | -19 | -61 | -34 | -19 | -40 | -53 | -57 | -53 | -49 | 1,608 | -51 | 23 | 22 | 18 | 13 | -8 | -2 | -2 | -17 | 5 | 4 | 0 | 7 |
| Tax | 3 | -2 | 5 | 3 | 3 | 2 | 2 | 9 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 371 | 5 | 8 | 3 | 31 | 2 | 1 | 1 | -0 | -1 | 0 | -0 | 2 | 3 |
| Net Profit | -35 | -97 | -16 | 186 | -28 | -75 | -21 | -70 | -34 | -19 | -40 | -54 | -57 | -53 | -49 | 1,238 | -56 | 16 | 19 | -13 | 11 | -8 | -2 | -2 | -16 | 5 | 4 | -2 | 4 |
| EPS in ₹ | -5.75 | -15.83 | -2.60 | 30.35 | -4.62 | -12.25 | -3.48 | -11.38 | -5.58 | -3.16 | -6.54 | -8.84 | -9.36 | -8.65 | -8.03 | 202.03 | -9.17 | 2.56 | 3.16 | -2.03 | 1.79 | -1.35 | -0.37 | -0.23 | -2.59 | 0.77 | 0.74 | -0.31 | 0.66 |
Panacea Biotec
Panacea Biotec
441.00
-2.60
(-0.59%)
Key Fundamentals
Market Cap
2,701.16 Cr
EPS
-1.37
PE Ratio
244.04
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
581.90
52 Week Low
277.50
PB Ratio
3.35
Debt to Equity
0.02
Sector
Pharmaceuticals Actual
Company News
View All News
Panacea Biotec received a ₹127.20 crore order from the Central Medical Services Society under the Ministry of Health and Family Welfare for supplying bivalent oral polio vaccine. The domestic order will be delivered over 90 to 480 days starting from October 8. Additionally, UNICEF awarded the company a long-term agreement worth approximately $35.65 million (₹315 crore) to supply polio vaccines from April 2026 to March 2030, with orders for Q2 CY2026 and CY2027 to be executed by CY2027. The company's shares traded marginally higher at ₹432.05.
Panacea Biotec has received an order worth ₹127.20 crore from CMSS for bivalent oral polio vaccine. The delivery will be completed in stages over a period ranging from 90 to 480 days.
Panacea Biotec Secures ₹315 Crore Order
Oct 03, 2025
Oct 03, 2025Panacea Biotec has secured an order worth ₹315 crore.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,697.30 | #1 4,07,239.12 | 39.01 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,598.50 | 1,75,169.44 | 75.90 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,645.30 | 1,32,899.78 | 24.96 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,626.90 | 1,22,750.78 | 60.69 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,281.80 | 1,06,980.79 | #1 18.74 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
1,011.65 | 1,01,795.66 | 21.36 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
2,455.60 | 1,01,356.97 | 52.80 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
1,949.30 | 89,035.16 | 23.85 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,555.50 | 66,424.34 | 28.44 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,106.00 | 64,236.66 | 19.03 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-0.89 %
Net Income Growth
480.00 %
Cash Flow Change
-888.76 %
ROE
483.33 %
ROCE
-181.48 %
EBITDA Margin (Avg.)
-192.86 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,931 | 1,854 | 1,800 | 1,608 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
| Fixed Assets | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 567 |
| Current Assets | 526 | 549 | 533 | 560 | 508 | 683 | 511 | 951 | 562 | 486 | 545 |
| Capital Work in Progress | 156 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 128 |
| Investments | 5 | 4 | 7 | 7 | 5 | 6 | 0 | 5 | 14 | 40 | 3 |
| Other Assets | 626 | 619 | 761 | 611 | 542 | 703 | 534 | 1,115 | 615 | 517 | 592 |
| Total Liabilities | 1,931 | 1,854 | 1,800 | 1,608 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
| Current Liabilities | 706 | 475 | 588 | 691 | 938 | 452 | 449 | 776 | 330 | 309 | 367 |
| Non Current Liabilities | 750 | 930 | 846 | 611 | 90 | 743 | 960 | 109 | 101 | 94 | 92 |
| Total Equity | 475 | 450 | 366 | 306 | 347 | 196 | -232 | 874 | 840 | 838 | 831 |
| Reserve & Surplus | 449 | 426 | 340 | 293 | 335 | 139 | -257 | 849 | 816 | 814 | 807 |
| Share Capital | 22 | 22 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -11 | 7 | 35 |
| Investing Activities | -37 | 17 | -26 | 55 | -6 | -35 | -48 | 1,283 | 430 | 7 | 65 |
| Operating Activities | 37 | 91 | 131 | 118 | 105 | -31 | 107 | -108 | -423 | 4 | -27 |
| Financing Activities | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 | -3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.46 % | 72.87 % | 72.49 % | 72.48 % | 72.48 % | 72.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.27 % | 0.27 % | 0.37 % | 0.38 % | 1.16 % | 0.78 % | 1.06 % |
| DIIs | 1.27 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.29 % | 0.43 % | 0.43 % | 0.54 % | 0.00 % | 0.00 % | 0.84 % | 1.07 % | 1.16 % | 1.17 % | 1.49 % | 1.52 % | 1.81 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 17.34 % | 15.21 % | 15.57 % | 15.99 % | 15.14 % | 15.60 % | 15.79 % | 15.97 % | 15.82 % | 16.15 % | 19.20 % | 19.63 % | 19.90 % | 20.42 % | 18.11 % | 18.98 % | 18.45 % | 18.17 % | 17.69 % |
| Others | 7.80 % | 11.20 % | 10.84 % | 10.42 % | 11.27 % | 10.81 % | 10.33 % | 10.02 % | 10.16 % | 9.73 % | 7.21 % | 6.78 % | 5.40 % | 4.79 % | 7.49 % | 6.99 % | 6.41 % | 7.05 % | 6.96 % |
| No of Share Holders | 27,228 | 54,313 | 52,816 | 52,465 | 49,563 | 49,896 | 49,078 | 50,533 | 48,634 | 47,815 | 48,878 | 47,091 | 46,242 | 45,513 | 39,982 | 35,446 | 33,593 | 34,256 | 33,593 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 332.95 | 273.05 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 349.80 | 349.80 |
| 13 Nov 2024 | Quarterly Result Announcement | NA | 13 Nov 2024 | 303.15 | 340.50 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 324.90 | 343.15 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 528.95 | 520.90 |
| 14 Aug 2025 | Quarterly Result Announcement | NA | 14 Aug 2025 | 400.65 | 430.65 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 425.45 | 405.60 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderOct 09, 2025
Oct 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Demat Status Report For The Month Of September 2025Oct 07, 2025
Oct 07, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderOct 03, 2025
Oct 03, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMOct 01, 2025
Oct 01, 2025Proceedings Of The 41St Annual General Meeting Held On September 30 2025Sep 30, 2025
Sep 30, 2025Disclosure Under Regulation 30 Of SEBI LODR RegulationsSep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Launch Of IndiaS First 100% Toxin-Free And Safe Nikomom Baby Skin Care Products And Staart Prime Infant Milk Substitute Product By CompanyS Wholly-Owned Subsidiary Panacea Biotec Pharma LimitedSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Sep 24, 2025Communication Sent To Physical Shareholders To Furnish PAN And KYC DetailsSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Sep 09, 2025Demat Status Report For The Month Of August 2025Sep 08, 2025
Sep 08, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 08, 2025
Sep 08, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 08, 2025
Sep 08, 2025Reg. 34 (1) Annual Report.Sep 08, 2025
Sep 08, 2025Intimation Of 41St Annual General Meeting Of The Company To Be Held On Tuesday September 30 2025 At 11:30 A.M. (IST) Through Video Conferencing (VC) / Other Audio Visual Means (OAVM)Sep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 16, 2025
Aug 16, 2025Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter Ended 30.06.2025Aug 14, 2025
Aug 14, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On August 14 2025Aug 14, 2025
Aug 14, 2025Demat Status Report For The Month Of July 2025Aug 07, 2025
Aug 07, 2025Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30 2025Aug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Intimation Under Regulation 30 And Regulation 31A(8) Of The Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations 2015 - Approval For Reclassification Of Mrs. Sunanda Jain Mr. Sumit Jain And Ms. Radhika Jain FroJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Jul 19, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 11, 2025
Jul 11, 2025Intimation Of Settlement Of Disputes With Apotex Inc. Canada
Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 09, 2025
Jul 09, 2025Details Of Shares Dematerialised During June 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jul 07, 2025
Jul 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Details Of Shares Dematerialised During May 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jun 06, 2025
Jun 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Intimation Regarding Appointment Of Secretarial AuditorMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025May 30, 2025
May 30, 2025Board Meeting Outcome for 1. Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025
2. Passing Over Of Dividend For The Financial Year 2024-25
3. Appointment Of SecretarMay 30, 2025
May 30, 2025Board Meeting Intimation for For Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31 2025 And Passing Over Of Dividend On Equity As Well As Preference Shares For The Said Financial Year.May 24, 2025
May 24, 2025Nation-Wide Study Undertaken By Panacea Biotec Pharma Ltd. (Material WOS) Confirms Chilrun Full Accelerates Growth And Development In ChildrenMay 19, 2025
May 19, 2025Details Of Shares Dematerialized During April 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018May 06, 2025
May 06, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Apr 29, 2025Receipt Of An Additional Award From UNICEF For Supply Of Bivalent Oral Polio Vaccine (Bopv) Worth ~US$ 5.20 Million In Q3 CY2025Apr 23, 2025
Apr 23, 2025Details Of Shares Dematerialized During March 2025Apr 07, 2025
Apr 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Apr 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Apr 01, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Mar 31, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.05% | 223 | 0.05% | 0.05% |
Technical Indicators
RSI(14)
Neutral 56.76
ATR(14)
Less Volatile 17.43
STOCH(9,6)
Neutral 62.35
STOCH RSI(14)
Neutral 64.85
MACD(12,26)
Bullish 1.40
ADX(14)
Strong Trend 27.35
UO(9)
Bearish 53.41
ROC(12)
Uptrend And Accelerating 6.83
WillR(14)
Neutral -31.15
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
